公开(公告)号：US20230257479A1

公开(公告)日：2023-08-17

申请号：US17642488

申请日：2020-09-11

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C.W. BREIJ ,  Bart E.C.G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN ,  Reshma Abdulla RANGWALA ,  Sri GHATTA ,  Ruud BRAKENHOFF ,  Rieneke VAN DE VEN

IPC: C07K16/30 ,  A61P35/00 ,  A61P1/00

CPC classification number: C07K16/30 ,  A61P1/00 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention relates to multispecific antibodies binding to 5T4 and CD3 for use in the treatment of cancer selected from the group consisting of esophageal cancer, Non-small Cell Lung Cancer (NSCLC) and Squamous Cell Carcinoma of the Head and Neck (SCCHN).

公开(公告)号：US20210070877A1

公开(公告)日：2021-03-11

申请号：US17077376

申请日：2020-10-22

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20210230296A1

公开(公告)日：2021-07-29

申请号：US17228023

申请日：2021-04-12

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  A61P35/00 ,  C12N15/79

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20200277397A1

公开(公告)日：2020-09-03

申请号：US16813167

申请日：2020-03-09

Applicant: GENMAB A/S

Inventor： David SATIJN ,  Esther C. W. BREIJ ,  Bart E. C. G. DE GOEIJ ,  Kristel KEMPER ,  Patrick ENGELBERTS ,  Edward N. VAN DEN BRINK ,  Rik RADEMAKER ,  Dennis VERZIJL ,  Sjeng HORBACH ,  Paul PARREN

IPC: C07K16/30 ,  C12N15/79 ,  A61P35/00

Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.